Current Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy

Area of Science:

• Medical Mycology
• Infectious Diseases
• Pharmacology

Background:

• Fungal infections are an increasing global health concern, particularly for immunocompromised and medically treated individuals.
• Limited selective targets in eukaryotic fungi restrict antifungal drug development.
• Current antifungal arsenal (polyenes, azoles, echinocandins, flucytosine) faces challenges including toxicity, drug interactions, and emerging resistance.

Purpose of the Study:

• To provide a concise overview of the current landscape of antifungal therapies.
• To summarize antifungal agents in various stages of clinical development.
• To explore novel antifungal targets and strategies for future therapeutic interventions.

Main Methods:

• Literature review of existing antifungal drugs.
• Analysis of agents currently undergoing clinical trials.
• Exploration of emerging research on potential new antifungal targets.

Main Results:

• The current antifungal drug market is limited, with significant challenges in efficacy and resistance.
• Several novel antifungal candidates are in different phases of clinical development.
• Research is actively pursuing new molecular targets and innovative strategies to overcome resistance.

Conclusions:

• There is an urgent need for new and effective antifungal agents due to increasing resistance and limited treatment options.
• Continued research into novel targets and drug development is crucial to address the growing threat of invasive fungal infections.
• A multi-pronged approach combining existing and novel therapies is essential for effective antifungal treatment.